ES2070266T3 - Vacuna contra la infeccion por escherichia coli. - Google Patents

Vacuna contra la infeccion por escherichia coli.

Info

Publication number
ES2070266T3
ES2070266T3 ES90201990T ES90201990T ES2070266T3 ES 2070266 T3 ES2070266 T3 ES 2070266T3 ES 90201990 T ES90201990 T ES 90201990T ES 90201990 T ES90201990 T ES 90201990T ES 2070266 T3 ES2070266 T3 ES 2070266T3
Authority
ES
Spain
Prior art keywords
escherichia coli
vaccine against
against infection
toxin
coli
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90201990T
Other languages
English (en)
Spanish (es)
Inventor
Den Bosch Johannes Francis Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of ES2070266T3 publication Critical patent/ES2070266T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES90201990T 1989-08-18 1990-07-23 Vacuna contra la infeccion por escherichia coli. Expired - Lifetime ES2070266T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP89202110 1989-08-18

Publications (1)

Publication Number Publication Date
ES2070266T3 true ES2070266T3 (es) 1995-06-01

Family

ID=8202455

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90201990T Expired - Lifetime ES2070266T3 (es) 1989-08-18 1990-07-23 Vacuna contra la infeccion por escherichia coli.

Country Status (16)

Country Link
US (1) US5750115A (enExample)
EP (1) EP0413378B1 (enExample)
JP (1) JP3031561B2 (enExample)
KR (1) KR0177510B1 (enExample)
CN (1) CN1062605C (enExample)
AU (1) AU635062B2 (enExample)
CA (1) CA2022420C (enExample)
DE (1) DE69016129T2 (enExample)
DK (1) DK0413378T3 (enExample)
ES (1) ES2070266T3 (enExample)
GR (1) GR3015782T3 (enExample)
HU (2) HU210965B (enExample)
IL (1) IL95175A (enExample)
NZ (1) NZ234933A (enExample)
TW (1) TW204353B (enExample)
ZA (1) ZA906100B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2042718T3 (es) * 1987-10-26 1993-12-16 Akzo Nv Procedimiento para la preparacion de una vacuna para proteger aves de corral contra septicemia producida por e. coli.
US6749831B1 (en) * 1997-05-16 2004-06-15 Medical Defense Technology, Llc Vaccine against lipopolysaccharide core
JP2001527562A (ja) * 1997-05-16 2001-12-25 メディカル ディフェンス テクノロジーズ エルエルシー リポ多糖コアに対するワクチン
WO1999059626A1 (en) * 1998-05-15 1999-11-25 Mkb Investments Limited Partnership Compositions and method for immunizing poultry
US8828226B2 (en) 2003-03-01 2014-09-09 The Trustees Of Boston University System for assessing the efficacy of stored red blood cells using microvascular networks
EP1934349A4 (en) * 2005-08-30 2009-05-27 Commw Scient Ind Res Org BACTERIAL INTRODUCTION OF BIOLOGICALLY ACTIVE POLYPEPTIDES
US11284616B2 (en) 2010-05-05 2022-03-29 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
CN102905522A (zh) 2009-10-12 2013-01-30 新健康科学股份有限公司 用于从红细胞中除去氧的氧消耗装置和方法
US12089589B2 (en) 2009-10-12 2024-09-17 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US9199016B2 (en) 2009-10-12 2015-12-01 New Health Sciences, Inc. System for extended storage of red blood cells and methods of use
BR112012008683B8 (pt) 2009-10-12 2022-11-08 Hemanext Inc dispositivo de armazenagem de sangue para armazenar sangue depletado de oxigênio e dióxido de carbono, dispositivo de depleção de oxigênio e dióxido de carbono, método para remover oxigênio e dióxido de carbono de hemácias, sistema de armazenagem de sangue, dispositivo de armazenagem de sangue, método para remover oxigênio de hemácias e método para aumentar os níveis de adenosina trifosfato (atp) nas hemácias
WO2012027582A1 (en) 2010-08-25 2012-03-01 New Health Sciences Method for enhancing red blood cell quality and survival during storage
EP4218412A1 (en) 2010-11-05 2023-08-02 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US9067004B2 (en) 2011-03-28 2015-06-30 New Health Sciences, Inc. Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly
US8926980B2 (en) * 2011-07-11 2015-01-06 Camas Incorporated Compositions against bacterial toxins
AU2012294269B2 (en) 2011-08-10 2016-11-24 Hemanext Inc. Integrated leukocyte, oxygen and/or CO2 depletion, and plasma separation filter device
CA2902061C (en) 2013-02-28 2023-08-08 New Health Sciences, Inc. Gas depletion and gas addition devices for blood treatment
KR20250033333A (ko) 2015-03-10 2025-03-07 헤마넥스트 인코포레이티드 산소 감소 1회용 키트, 장치 및 이의 사용 방법
BR122022005103B1 (pt) 2015-04-23 2023-03-14 Hemanext Inc Dispositivo de armazenamento de sangue para armazenar sangue depletado de oxigênio e método para armazenar sangue depletado de oxigênio
PT3297641T (pt) 2015-05-18 2025-10-09 Hemanext Inc Métodos de armazenamento de sangue total e respetivas composições
CN109195632A (zh) 2016-05-27 2019-01-11 新健康科学股份有限公司 厌氧血液储存和病原体失活方法
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58135819A (ja) * 1982-02-09 1983-08-12 Nisshin Flour Milling Co Ltd 鶏の大腸菌症の予防法
US4772464A (en) * 1985-08-01 1988-09-20 Miles Laboratories, Inc. Protective antibodies to serotypic determinants of flagellar antigens
US4702911A (en) 1985-09-27 1987-10-27 Immunomed Corporation Preparation of bacterium pili subunits and vaccines containing pili subunits
ES2060580T3 (es) * 1986-03-11 1994-12-01 Shionogi & Co Adn que tiene una secuencia adn codificante de la proteina flagelina y vector que la contiene.

Also Published As

Publication number Publication date
CA2022420C (en) 2000-03-28
TW204353B (enExample) 1993-04-21
GR3015782T3 (en) 1995-07-31
AU635062B2 (en) 1993-03-11
HU210965B (en) 1995-09-28
JPH03184996A (ja) 1991-08-12
HU905053D0 (en) 1991-01-28
DE69016129D1 (de) 1995-03-02
AU6109990A (en) 1991-02-21
US5750115A (en) 1998-05-12
JP3031561B2 (ja) 2000-04-10
ZA906100B (en) 1991-05-29
NZ234933A (en) 1992-06-25
EP0413378B1 (en) 1995-01-18
IL95175A (en) 1994-05-30
CN1049523A (zh) 1991-02-27
HUT59612A (en) 1992-06-29
EP0413378A1 (en) 1991-02-20
HU211827A9 (en) 1995-12-28
DK0413378T3 (da) 1995-05-15
DE69016129T2 (de) 1995-05-24
CN1062605C (zh) 2001-02-28
IL95175A0 (en) 1991-06-10
KR910004209A (ko) 1991-03-28
CA2022420A1 (en) 1991-02-19
KR0177510B1 (ko) 1999-03-20

Similar Documents

Publication Publication Date Title
NO20004972L (no) Derivater av pneumokokkale kolinbindende proteiner for vaksiner
CA2022420A1 (en) Escherichia coli vaccine
PA8549701A1 (es) Vacunacion en dosis unica con mycoplasma hyopneumoniae
CY1108147T1 (el) Εμβολιο κατα των σεξουαλικως μεταδιδομενων νοσων
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
ATE350057T1 (de) Impfstoffzusammesetzung
PA8549801A1 (es) Vacuna de mycoplasma bovis y metodos para reducir la neumonia en animales
ES2160601T3 (es) Vacunas de conjugado de polisacaridos de estreptococos del grupo b tipo ii y tipo v-proteina.
ES2137310T3 (es) Vacuna contra una infeccion por streptococcus suis.
BR0006291A (pt) Bactéria do gênero salmonella, vacina para aproteção de animais contra a salmonelose, uso deuma bactéria, e, processo para a preparação deuma vacina
AR020084A1 (es) Pestivirus atenuados
BR0110278A (pt) Composição de vacina, anticorpo ou anti-soro, métodos de produção de um anticorpo ou de um anti-soro e de imunização de um animal contra um ectoparasita que se alimenta de sangue, proteìna de cemento de carrapato, e, uso de uma proteìna de cemento de carrapato
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
ES2136064T3 (es) Vacunas de toxoide de pasteurella multocida.
ES2058100T3 (es) Vacuna combinada.
EP0600396A3 (en) Gut protozoan vaccines.
ECSP045083A (es) Nueva enfermedad bacteriana de las aves de corral
PT894500E (pt) Vacina para streptococcus equi
HUP9700975A2 (hu) Élő, legyengített, Pasteurellaceae családba tartozó, RTX-termelő baktériumok
ES2066206T3 (es) Utilizacion de adenilciclasa como vacunas contra bordetella.
BR9305075A (pt) Antígeno para conferir imunidade protetora contra infecções helmínticas em humanos e animais,e processo de vacinação para aplicação na imunoprofilaxia de doenças helmintológicas de interesse veterinário e médico
ES2089371T3 (es) Vacuna contra las enfermedades respiratorias para gatos.
DK0623170T3 (da) Vacciner baseret på streptokinase
ES2102836T3 (es) El empleo de vacunas antihelminticas en el control de la enfermedad parasitaria asociada con la perdida de la inmunidad natural.
PT636030E (pt) Vacina de bacterina-toxoide de pasteurella haemolytica tipo a-1

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 413378

Country of ref document: ES